Last reviewed · How we verify
Diffuse large B-cell lymphoma refractory
Approved treatments
- Xmab5574 · Morphosys Us Inc
Tafasitamab works by binding to the CD19 antigen on B-lymphocytes, triggering an immune response against cancer cells. - Polatuzumab · National Cancer Institute (NCI)
- Treanda · Baxter
Treanda works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow. - MONJUVI · MORPHOSYS US INC
- Polivy · Roche
Polivy works by binding to a protein on the surface of cancer cells and releasing a toxin that kills the cell. - Bendamustin · Meir Medical Center
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Diffuse large B-cell lymphoma refractory patent landscape — cliff calendar, originator estates, attackable patents
- Diffuse large B-cell lymphoma refractory treatment landscape brief
- Diffuse large B-cell lymphoma refractory treatment updates RSS
Frequently asked questions about Diffuse large B-cell lymphoma refractory
What drugs treat Diffuse large B-cell lymphoma refractory?
Tracked treatments include Xmab5574, Polatuzumab, Treanda, MONJUVI, Polivy, Bendamustin.
What is the treatment for Diffuse large B-cell lymphoma refractory?
Standard treatment for Diffuse large B-cell lymphoma refractory includes Xmab5574, Polatuzumab, Treanda, MONJUVI, Polivy. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Diffuse large B-cell lymphoma refractory patent cliff · Diffuse large B-cell lymphoma refractory CI report
- Treatment: Xmab5574 · Morphosys Us Inc
- Treatment: Polatuzumab · National Cancer Institute (NCI)
- Treatment: Treanda · Baxter
- Treatment: MONJUVI · MORPHOSYS US INC
- Treatment: Polivy · Roche
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing